Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBP) generates a steady flow of news as a clinical-stage biopharmaceutical company developing allogeneic gamma-delta T cell therapies for cancer and other indications. News coverage on this page focuses on the company’s clinical progress, strategic initiatives, and capital markets developments, helping readers follow how its gamma-delta T cell platform is advancing from early-stage research into later-stage trials and potential new indications.
Many updates relate to TCB008, the company’s lead gamma-delta T cell therapy candidate. Articles highlight milestones in the ACHIEVE Phase II UK clinical trial, including completion of dosing in Cohort A for relapsed or refractory acute myeloid leukemia patients, initial dosing and follow-up in Cohort B minimal residual disease patients, safety findings with no reported drug-related adverse events, and efficacy signals such as stable disease and complete molecular remission in at least one MRD patient. These reports provide insight into how TCB008 is performing in challenging hematologic malignancies.
Other news items cover strategic and corporate actions, such as TC BioPharm’s intention to conduct proof-of-concept preclinical studies of TCB008 in H5N1 (avian “bird flu”), a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved glaucoma treatment, and operational changes including a shift toward a CDMO-based manufacturing model and associated workforce reductions. Capital markets announcements, including an ADS ratio change and the company’s transition from Nasdaq to trading on OTC Markets, are also reported.
Investors and observers can use this news feed to track clinical data readouts, expansion into new therapeutic areas, proposed M&A activity, and listing or ADS structure changes. For those following TCBP, revisiting this page offers a consolidated view of how the company’s gamma-delta T cell programs and broader strategy evolve over time.
TC Biopharm has initiated the dosing of three patients in its Phase 2b clinical trial of OmnImmune®, targeting Acute Myeloid Leukemia (AML). This trial includes a safety cohort of five patients, with results expected by the end of 2022. Following this, the study will move to open enrollment in January 2023, aiming to enroll around 37 patients, including those with myelodysplastic syndromes. The trial represents a pivotal step in TC Biopharm's strategy to advance its innovative gamma-delta T cell therapies.
TC BioPharm (NASDAQ: TCBP) has appointed a new Scientific Advisory Board (SAB) to enhance its gamma-delta T cell therapies for cancer treatment. The SAB, which includes experts from leading institutions, will focus on advancing clinical trials and establishing strategic partnerships in cell therapy. CEO Bryan Kobel highlighted the potential for growth in gamma-delta platform therapies. The company is already conducting pivotal trials for its OmnImmune® product, targeting acute myeloid leukemia, leveraging its proprietary CryoTC technology to enhance treatment delivery.
TC BioPharm (NASDAQ: TCBP) announced its management will present at the Dawson James 7th Annual Small Cap Growth Conference and the LD MICRO Main Event XV. These events provide opportunities for one-on-one meetings with institutional investors. The Dawson James conference takes place on October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida, while the LD MICRO event is on October 26, 2022, at the Luxe Sunset Blvd Hotel in Los Angeles, California. TC BioPharm specializes in gamma-delta T cell therapies for cancer, with promising developments in clinical trials.
TC Biopharm (NASDAQ: TCBP) announced that the UK regulatory body MHRA has approved an 18-month extrapolated shelf life for its allogeneic cell therapy product, OmnImmune®. This approval allows the company to store and ship the product for clinical trials and future patient treatments, enhancing operational efficiency and scaling. This milestone underscores TC Biopharm's commitment to advancing gamma-delta T cell therapies in oncology and positions OmnImmune® as a leading 'off-the-shelf' cell therapy. CEO Bryan Kobel highlighted this approval as a validation of the company's ongoing development efforts.
TC Biopharm (Holdings) PLC (NASDAQ: TCBP) announced that CEO Bryan Kobel will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 am. The company is focused on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting pivotal clinical trials, including a Phase 2b/3 trial for OmnImmune® in acute myeloid leukemia. A webcast of the presentation will be available on TC BioPharm's Investor Relations page.
TC Biopharm, a clinical-stage biotechnology firm, will present at the 3rd Gamma Delta T Therapies Summit in Boston from July 26-28, 2022. Key executives, including Emilio Cosimo, Dr. Michael Leek, and Angela Scott, will lead multiple sessions covering gamma-delta T cell therapies for cancer. The summit is expected to gather over 120 leaders in the field, emphasizing TC Biopharm's position as a leader in gamma-delta T cell therapy development with ongoing clinical trials for cancer treatments.
TC BioPharm (NASDAQ: TCBP) will have its CEO, Bryan Kobel, participate in a fireside chat at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" on July 13, 2022. The session, moderated by Caroline Peachey, will address TC BioPharm's growth as a cell and gene therapy startup, quality control challenges, and advice for industry peers. TC BioPharm focuses on developing gamma-delta T cell therapies, including its promising product OmnImmune®, which targets relapse/refractory Acute Myeloid Leukemia and has received positive trial feedback and orphan drug status from the FDA.
TC Biopharm (NASDAQ: TCBP) announced the closure of its underwritten public offering of 10 million American Depositary Shares (ADSs) at $0.40 each, generating gross proceeds of $4 million. The offering allows underwriters a 45-day option to purchase an additional 1.5 million ADSs. This funding is intended to support the development of gamma-delta T cell therapies for cancer. The company is recognized as a leader in this field and is conducting phase II/III clinical trials for its OmnImmune® treatment in acute myeloid leukemia.
TC BioPharm (NASDAQ: TCBP) has announced the pricing of a public offering involving 10 million American Depositary Shares (ADSs) at $0.40 each, totaling $4 million in gross proceeds. The offering is set to close around June 7, 2022, pending customary conditions. The underwriters have a 45-day option to purchase an additional 1.5 million ADSs. The company specializes in developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials and a strong intellectual property portfolio.
TC Biopharm (NASDAQ: TCBP) announced a significant rise in acute myeloid leukemia (AML) diagnoses globally, increasing by 34.6% among men and 7.9% among women from 1990 to 2019, according to a recent study. In response, the Company highlighted the urgency for innovative cancer therapeutics, specifically its allogeneic gamma-delta T cell therapy, OmnImmune, currently in Phase 2B/3 trials. The FDA has granted Orphan Drug status to OmnImmune, with promising early results indicating low toxicity and potential effectiveness as a standalone and combination therapy. The Company aims to launch this treatment in 2023.
FAQ
What is the current stock price of TC BioPharm (Holdings) (TCBP)?
What is the market cap of TC BioPharm (Holdings) (TCBP)?
